| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803097601024 | 309760102 | ONELAR GR.CAP 30MG/CAP BTx28 (PVC/PE/PVDC-Alu transparent Blister) | 4.66 | 4.89 | 6.74 |
| 05/2018 | 2803097601031 | 309760103 | ONELAR GR.CAP 30MG/CAP BTx30 (PVC/PE/PVDC-Alu transparent Blister) | 4.84 | 05.08 | 7.00 |
| 05/2018 | 2803097602021 | 309760202 | ONELAR GR.CAP 60MG/CAP BTx28 (PVC/PE/PVDC-Alu transparent Blister) | 7.48 | 7.85 | 10.82 |
| 05/2018 | 2803097602038 | 309760203 | ONELAR GR.CAP 60MG/CAP BTx30 (PVC/PE/PVDC-Alu transparent Blister) | 7.76 | 8.14 | 11.21 |
For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.
Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.
Oral, rat LD<sub>50</sub>: 491 mg/kg for males and 279 mg/kg for females. Symptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
Orally administered duloxetine hydrochloride is well absorbed.
12 hours (range 8-17 hours)
Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.
* 1640 L